Please login to the form below

Not currently logged in
Email:
Password:

Quintiles acquires US CRO Novella Clinical

Deal will boost its small biopharma, oncology and medical device capabilities

Pharmaceutical services company Quintiles has bolstered its contract research capabilities with the acquisition of Novella Clinical for an undisclosed amount.

The US-headquartered contract research organisation (CRO) has more than 800 employees across North America and Europe and focuses on oncology, medical devices and diagnostics sectors

Quintiles, which said the deal would help it stay ahead of the diverse and evolving needs of its global customer base, also expects a boost for its small biopharma capabilities.

Paula Brown Stafford, president, clinical development at Quintiles, said: “The expertise and insight the Novella team brings will be a strong addition to our existing capabilities and help further differentiate Quintiles in an increasingly competitive marketplace.

“Novella's understanding of emerging companies, as well as our shared commitment to quality, customer service, and above all, the patients we ultimately serve, makes this acquisition a good fit for both organisations.”

Founded 15 years ago, Novella is a full-service CRO whose offerings include clinical monitoring, data management, regulatory affairs, qualify assurance and safety management.

Once the acquisition is completed Novella will operate as a standalone unit within Quintiles under its existing name.

23rd August 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics